drugset / Trial / NCT07508488
Deucravacitinib in the Treatment of Cicatricial Alopecias
Phase 2
Recruiting
20 enrolled
Icahn School of Medicine at Mount Sinai
Bristol-Myers Squibb · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a prospective, open-label clinical trial, in which all participants will be treated with deucravacitinib for 48 weeks. Approximately 20 participants will be enrolled: 10 Central Centrifugal Cicatricial Alopecia (CCCA) and 10 Frontal Fibrosing Alopecia (FFA). The study will take place at the Icahn School of Medicine at Mount Sinai (ISMMS). At the Baseline/Day 0 visit, participants will initiate treatment with deucravacitinib. All participants will receive deucravacitinib 12mg once-daily for 48 weeks. The treatment period will conclude at week 48.
Timeline
- Start
- 2026-05-28
- Primary completion
- 2028-06-30
- Completion
- 2028-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CRAVACITINIB | Small molecule | 6 mg | Oral |
| Subject | CRAVACITINIB | Small molecule | 12 mg | Oral |